Dose Intensification of Subcutaneous Vedolizumab is an Effective and Safe Option in Inflammatory Bowel Disease Patients: Results from the Multicentre OPTI-VEDO Study
JOURNAL OF CROHNS & COLITIS(2025)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined